The safety, tolerability and pharmacokinetics (plasma and urine) of a single intravenous infusion of 20, 70, 200, 400 and 700 µg/kg XG-104 administered to healthy male volunteers in a randomized, double-blind, placebo-controlled, dose escalating Phase I study

Trial Profile

The safety, tolerability and pharmacokinetics (plasma and urine) of a single intravenous infusion of 20, 70, 200, 400 and 700 µg/kg XG-104 administered to healthy male volunteers in a randomized, double-blind, placebo-controlled, dose escalating Phase I study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs XG 104 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Xigen
  • Most Recent Events

    • 22 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top